$2.65 Billion is the total value of HealthCor Management, L.P.'s 52 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 87.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| EW | Buy | EDWARDS LIFESCIENCES CORP | $137,661,000 | +19.8% | 625,990 | +0.6% | 5.20% | +16.7% |
| MRK | Buy | MERCK & CO INC | $131,177,000 | +21.0% | 1,558,290 | +20.6% | 4.96% | +17.9% |
| BIIB | New | BIOGEN INCcall | $128,051,000 | – | 550,000 | +100.0% | 4.84% | – |
| ISRG | New | INTUITIVE SURGICAL INC | $126,994,000 | – | 235,205 | +100.0% | 4.80% | – |
| VRTX | Buy | VERTEX PHARMACEUTICALS INC | $115,153,000 | +16.6% | 679,690 | +26.2% | 4.35% | +13.6% |
| ZBH | New | ZIMMER BIOMET HLDGS INC | $99,297,000 | – | 723,370 | +100.0% | 3.75% | – |
| DHR | Buy | DANAHER CORPORATION | $99,221,000 | +36.7% | 686,980 | +35.3% | 3.75% | +33.2% |
| BAX | New | BAXTER INTL INC | $90,341,000 | – | 1,032,820 | +100.0% | 3.42% | – |
| BIIB | New | BIOGEN INC | $83,084,000 | – | 356,860 | +100.0% | 3.14% | – |
| LH | New | LABORATORY CORP AMER HLDGS | $79,545,000 | – | 473,480 | +100.0% | 3.01% | – |
| CHNG | Buy | CHANGE HEALTHCARE INC | $51,394,000 | +30.9% | 4,254,430 | +58.1% | 1.94% | +27.5% |
| CRL | Buy | CHARLES RIV LABS INTL INC | $48,363,000 | -6.5% | 365,360 | +0.3% | 1.83% | -8.9% |
| BLUE | Buy | BLUEBIRD BIO INC | $46,561,000 | -0.6% | 507,090 | +37.8% | 1.76% | -3.1% |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $44,774,000 | +24.1% | 609,417 | +59.3% | 1.69% | +20.9% |
| JNJ | New | JOHNSON & JOHNSON | $44,447,000 | – | 343,540 | +100.0% | 1.68% | – |
| WMGI | Buy | WRIGHT MED GROUP N V | $42,546,000 | +1326.8% | 2,062,360 | +1962.4% | 1.61% | +1286.2% |
| IQV | Buy | IQVIA HLDGS INC | $40,923,000 | -0.6% | 273,950 | +7.0% | 1.55% | -3.2% |
| HOLX | New | HOLOGIC INC | $40,875,000 | – | 809,570 | +100.0% | 1.54% | – |
| ALC | Buy | ALCON INC | $32,581,000 | -0.3% | 558,940 | +6.1% | 1.23% | -2.8% |
| QGEN | New | QIAGEN NV | $20,247,000 | – | 614,110 | +100.0% | 0.76% | – |
| NUVA | Buy | NUVASIVE INC | $19,071,000 | +30.5% | 300,905 | +20.5% | 0.72% | +27.2% |
| SYK | Buy | STRYKER CORP | $18,838,000 | +174.8% | 87,090 | +161.1% | 0.71% | +167.7% |
| VRAY | Buy | VIEWRAY INC | $14,181,000 | -64.7% | 4,890,100 | +7.1% | 0.54% | -65.6% |
| GMAB | New | GENMAB A Ssponsored ads | $14,118,000 | – | 696,835 | +100.0% | 0.53% | – |
| STML | Buy | STEMLINE THERAPEUTICS INC | $12,948,000 | -21.0% | 1,243,780 | +16.2% | 0.49% | -23.1% |
| NVST | New | ENVISTA HLDGS CORP | $8,364,000 | – | 300,000 | +100.0% | 0.32% | – |
| RTIX | New | RTI SURGICAL HOLDINGS INC | $6,152,000 | – | 2,158,644 | +100.0% | 0.23% | – |
| ZGNX | New | ZOGENIX INC | $5,245,000 | – | 130,990 | +100.0% | 0.20% | – |
| AUPH | New | AURINIA PHARMACEUTICALS INC | $4,445,000 | – | 832,370 | +100.0% | 0.17% | – |
| PTE | Buy | POLARITYTE INC | $2,055,000 | -37.3% | 636,110 | +10.6% | 0.08% | -38.6% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| HCA HOLDINGS INC | 27 | Q1 2022 | 6.2% |
| ZIMMER HLDGS INC | 26 | Q2 2022 | 9.3% |
| DANAHER CORPORATION | 26 | Q3 2022 | 5.6% |
| NEUROCRINE BIOSCIENCES INC | 26 | Q4 2022 | 7.8% |
| UNITEDHEALTH GROUP INC | 24 | Q3 2022 | 6.4% |
| VERTEX PHARMACEUTICALS INC | 24 | Q3 2021 | 5.3% |
| HUMANA INC | 22 | Q3 2022 | 6.6% |
| BRISTOL-MYERS SQUIBB CO | 22 | Q3 2022 | 9.2% |
| BIOGEN INC | 21 | Q3 2022 | 8.5% |
| LABORATORY CORP AMER HLDGS | 20 | Q2 2020 | 8.3% |
View HealthCor Management, L.P.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CareView Communications Inc | May 26, 2023 | 186,970,000 | 32.0% |
| Research Alliance Corp. IISold out | February 14, 2023 | 0 | 0.0% |
| ARYA Sciences Acquisition Corp IVSold out | February 14, 2022 | 0 | 0.0% |
| Aurinia Pharmaceuticals Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| MADRIGAL PHARMACEUTICALS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Medicus Sciences Acquisition Corp.Sold out | February 14, 2022 | 0 | 0.0% |
| Arcturus Therapeutics Holdings Inc.Sold out | February 12, 2021 | 0 | 0.0% |
| Intersect ENT, Inc.Sold out | February 12, 2021 | 0 | 0.0% |
| NEVRO CORP | February 12, 2021 | 156,046 | 0.5% |
| ViewRay, Inc.Sold out | February 12, 2021 | 0 | 0.0% |
View HealthCor Management, L.P.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2023-05-26 |
| 4 | 2023-05-26 |
| SC 13D/A | 2023-05-26 |
| 4 | 2023-04-04 |
| 4 | 2023-04-04 |
| SC 13D/A | 2023-04-03 |
| 13F-HR | 2023-02-15 |
| SC 13G/A | 2023-02-14 |
| 4 | 2023-01-04 |
| 4 | 2023-01-04 |
View HealthCor Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.